TL;DR: Aetna, a CVS Health company, modified CPB 0825 governing cardiopulmonary exercise testing (CPET), effective December 5, 2025. If your team bills CPT 94621 for Aetna members, your medical necessity documentation requirements just changed.
Aetna updated its CPET coverage policy under CPB 0825 Aetna to expand the list of covered indications for CPT 94621—the primary code for cardiopulmonary exercise testing. The revised policy now explicitly covers Long COVID evaluation, sports eligibility after COVID-19 myocarditis, and interstitial lung disease functional evaluation, among other additions. This matters because CPET claims are high-scrutiny: the test has a broad differential and Aetna draws hard lines between covered and experimental use.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Cardiopulmonary Exercise Testing — CPB 0825 |
| Policy Code | CPB 0825 |
| Change Type | Modified |
| Effective Date | December 5, 2025 |
| Impact Level | High |
| Specialties Affected | Cardiology, Pulmonology, Cardiac Rehab, Thoracic Surgery, Pediatric Cardiology |
| Key Action | Audit your CPT 94621 claim documentation to confirm the diagnosis maps to a covered indication before billing |
Aetna Cardiopulmonary Exercise Testing Coverage Criteria and Medical Necessity Requirements 2025
Aetna's CPET coverage policy sets a clear prerequisite before CPT 94621 is billable: standard testing must come first. That means echocardiography, pulmonary function testing with diffusion capacity measurement, and a 6-minute walk test with oxygen desaturation measurement. CPET is not a first-line workup under this policy. Document that standard testing was done and was either inconclusive or insufficient before you submit.
Once that prerequisite is met, Aetna considers CPET medically necessary for 14 specific indications. These span cardiology, pulmonology, transplant evaluation, and pediatric congenital heart disease. The breadth is real—but so is the specificity. A vague diagnosis like "exertional dyspnea" without documented prior workup will get denied.
The 14 covered indications under CPB 0825:
| # | Covered Indication |
|---|---|
| 1 | Post-operative evaluation after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension |
| 2 | Exercise prescription development for cardiac or pulmonary rehabilitation in patients with cardiovascular disease or chronic pulmonary disease |
| 3 | Differentiating cardiac vs. pulmonary causes of exercise-induced dyspnea or impaired exercise capacity when standard testing is inconclusive |
| 4 | Evaluation of exercise capacity and therapy response in chronic heart failure (CHF) patients being considered for heart transplantation or other advanced therapies |
| 5 | Evaluation of children and adolescents with congenital heart disease — to discriminate between pulmonary and cardiovascular causes of exercise limitation, and to assess post-surgical improvement |
| 6 | Evaluation of specific adults with congenital heart disease, including: functional assessment of pulmonary arterial hypertension in congenital heart disease (CHD-PAH), follow-up of surgically corrected transposition of the great arteries, d-transposition of the great arteries, atrioventricular septal defect, and Tetralogy of Fallot, and evaluation of Eisenmenger physiology |
| 7 | Evaluation of individuals with heart failure where the contribution of heart failure to exercise limitations is uncertain |
| 8 | Evaluation of lung transplant or lung resection candidates when predicted post-operative FEV1 or DLCO is below 30%, or when stair-climbing or shuttle walk test results are unsatisfactory |
| 9 | Evaluation of mitochondrial myopathies |
| 10 | Evaluation of post-acute sequelae of COVID-19 (Long COVID) |
| 11 | Evaluation of sports eligibility in patients who had myocarditis with COVID-19 |
| 12 | Follow-up of patients after a Fontan procedure (see CPT 33615 and 33617 for related surgical codes) |
| 13 | Functional evaluation of COPD when specific questions remain after reviewing basic clinical data—history, physical exam, chest X-ray, PFTs, and resting ECG |
| 14 | Functional and prognostic evaluation of interstitial lung disease when specific questions remain after reviewing basic clinical data |
Long COVID and COVID-related myocarditis are explicit covered indications. If you treat those patients and haven't been billing CPT 94621 for CPET, review your encounter data now. This is reimbursement you may be leaving behind.
The prior authorization requirements for CPT 94621 under Aetna vary by plan. Check the member's specific benefit document. For employer-sponsored and individual Aetna plans, prior auth is commonly required for CPET—don't assume the covered indication alone clears the path. Confirm prior auth status before scheduling.
Aetna Cardiopulmonary Exercise Testing Exclusions and Non-Covered Indications
This is where Aetna's CPET coverage policy draws the line. The policy explicitly labels several indications as experimental, investigational, or unproven. Billing CPT 94621 for these will result in claim denial.
Aetna considers CPET experimental for:
| # | Excluded Procedure |
|---|---|
| 1 | Evaluation of candidates for allogeneic stem cell transplantation |
| 2 | Evaluation of individuals with newly diagnosed Marfan syndrome |
The policy notes this is not an all-inclusive list. That language matters. Aetna can deny CPT 94621 claims for indications not listed as covered even if they're not named in the experimental list. The safer read: if the indication isn't on the covered list, treat it as not covered until you get explicit confirmation.
Coverage Indications at a Glance
| Indication | Status | Key Code | Notes |
|---|---|---|---|
| Post-op study after pulmonary thromboendarterectomy (chronic thromboembolic PH) | Covered | CPT 94621 | Standard testing prerequisite required |
| Exercise prescription for cardiac/pulmonary rehab | Covered | CPT 94621 | Must have CV or chronic pulmonary disease |
| Differentiating cardiac vs. pulmonary dyspnea (inconclusive standard workup) | Covered | CPT 94621 | Standard testing must be inconclusive |
| CHF — evaluation for heart transplant or advanced therapy | Covered | CPT 94621 | Document transplant candidacy evaluation |
| Congenital heart disease — pediatric (post-surgical assessment) | Covered | CPT 94621 | Includes exercise tolerance after surgery |
| Congenital heart disease — adult (CHD-PAH, TGA, AVSD, TOF, Eisenmenger) | Covered | CPT 94621 | Specific diagnoses required |
| Heart failure — uncertain contribution to exercise limitation | Covered | CPT 94621 | Document clinical uncertainty |
| Lung transplant / lung resection candidates (FEV1 or DLCO <30%) | Covered | CPT 94621 | Or unsatisfactory stair-climb/shuttle walk |
| Mitochondrial myopathies | Covered | CPT 94621 | Confirm ICD-10 specificity |
| Long COVID (post-acute sequelae of COVID-19) | Covered | CPT 94621 | Explicit addition in updated policy |
| Sports eligibility — COVID-19 myocarditis | Covered | CPT 94621 | Diagnosis: B33.22 Viral myocarditis |
| Post-Fontan procedure follow-up | Covered | CPT 94621 | Related surgical CPT: 33615, 33617 |
| COPD — functional evaluation (questions persist after basic workup) | Covered | CPT 94621 | Document what remains unanswered after PFTs and ECG |
| Interstitial lung disease — functional and prognostic evaluation | Covered | CPT 94621 | Same workup documentation requirement as COPD |
| Allogeneic stem cell transplant candidacy | Experimental | CPT 94621 | Claim denial expected |
| Newly diagnosed Marfan syndrome | Experimental | CPT 94621 | Claim denial expected |
Aetna Cardiopulmonary Exercise Testing Billing Guidelines and Action Items 2025
The effective date for these changes is December 5, 2025. If you're billing CPT 94621 for Aetna members now, these steps apply immediately.
| # | Action Item |
|---|---|
| 1 | Audit your CPT 94621 charge capture against the 14 covered indications. Map each active CPET order to one of the covered indications. If the clinical indication doesn't match, flag it before the claim goes out. |
| 2 | Document the prerequisite standard testing in every chart supporting a CPET order. Aetna's medical necessity criteria require echocardiography, PFTs with DLCO, and a 6-minute walk test before CPET. If those aren't documented, you're billing without the foundation the policy requires. That's a denial waiting to happen. |
| 3 | Add Long COVID (post-acute sequelae of COVID-19) and COVID-19 myocarditis sports eligibility to your indication checklist. These are now explicit covered indications. Review your encounters from December 5, 2025 forward. If eligible patients had CPET ordered but weren't billed because the indication wasn't in your approved list, correct that now. |
| 4 | Verify prior authorization requirements before scheduling CPET for Aetna members. The coverage policy doesn't blanket-waive prior auth. Pull the member's benefit document or run an eligibility check. Missing a prior auth requirement is a clean-miss denial—the clinical documentation won't save you. |
| 5 | Flag allogeneic stem cell transplant candidacy evaluations at the order level. If an oncology or hematology team orders CPET for this indication, stop it before it hits your charge capture. Aetna explicitly considers this experimental. A denial is certain, and an ABN won't apply here—this is a non-covered service for this indication. |
| 6 | Update your ICD-10 pairing logic for COPD and interstitial lung disease claims. Both indications require documentation that "specific questions persist" after the basic clinical workup. A generic COPD diagnosis code with no supporting narrative won't survive a medical necessity review. Pair the ICD-10 with a clinical note that spells out what the basic workup didn't answer. |
| 7 | For congenital heart disease cases, get specific on diagnosis. Aetna covers CPET for adults with CHD-PAH, surgically corrected TGA, d-TGA, atrioventricular septal defect, Tetralogy of Fallot, and Eisenmenger physiology. Your ICD-10 code needs to match one of those specific diagnoses. A general congenital heart disease code without the right specificity will leave the claim exposed. If you're unsure how this maps to your patient mix, talk to your compliance officer before billing. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cardiopulmonary Exercise Testing Under CPB 0825
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 94621 | CPT | Cardiopulmonary exercise testing, including measurements of minute ventilation, CO2 production, O2 uptake |
Other CPT Codes Related to CPB 0825
These surgical codes appear in the policy in the context of Fontan procedure follow-up. CPET (CPT 94621) is covered for follow-up of patients who underwent these procedures.
| Code | Type | Description |
|---|---|---|
| 33615 | CPT | Repair of complex cardiac anomalies (e.g., tricuspid atresia) by closure of atrial septal defect and anastomosis of right atrium with pulmonary artery (Fontan procedure) |
| 33617 | CPT | Repair of complex cardiac anomalies (e.g., single ventricle) by modified Fontan procedure |
Key ICD-10-CM Diagnosis Codes
The policy lists 295 ICD-10-CM codes. Below are the codes explicitly provided in the policy data. Your billing team should cross-reference the full list in CPB 0825 for complete coverage.
| Code | Description |
|---|---|
| B33.22 | Viral myocarditis |
| C34.0 | Malignant neoplasm of bronchus and lung |
| C34.1 | Malignant neoplasm of bronchus and lung |
| C34.10 | Malignant neoplasm of bronchus and lung |
| C34.11 | Malignant neoplasm of bronchus and lung |
| C34.12 | Malignant neoplasm of bronchus and lung |
| C34.13 | Malignant neoplasm of bronchus and lung |
| C34.14 | Malignant neoplasm of bronchus and lung |
| C34.15 | Malignant neoplasm of bronchus and lung |
| C34.16 | Malignant neoplasm of bronchus and lung |
| C34.17 | Malignant neoplasm of bronchus and lung |
| C34.18 | Malignant neoplasm of bronchus and lung |
| C34.19 | Malignant neoplasm of bronchus and lung |
| C34.2 | Malignant neoplasm of bronchus and lung |
| C34.20 | Malignant neoplasm of bronchus and lung |
| C34.21 | Malignant neoplasm of bronchus and lung |
| C34.22 | Malignant neoplasm of bronchus and lung |
| C34.23 | Malignant neoplasm of bronchus and lung |
| C34.24 | Malignant neoplasm of bronchus and lung |
| C34.25 | Malignant neoplasm of bronchus and lung |
| C34.26 | Malignant neoplasm of bronchus and lung |
| C34.27 | Malignant neoplasm of bronchus and lung |
| C34.28 | Malignant neoplasm of bronchus and lung |
| C34.29 | Malignant neoplasm of bronchus and lung |
| C34.3 | Malignant neoplasm of bronchus and lung |
| C34.30 | Malignant neoplasm of bronchus and lung |
| C34.31 | Malignant neoplasm of bronchus and lung |
| C34.32 | Malignant neoplasm of bronchus and lung |
| C34.33 | Malignant neoplasm of bronchus and lung |
| C34.34 | Malignant neoplasm of bronchus and lung |
| C34.35 | Malignant neoplasm of bronchus and lung |
| C34.36 | Malignant neoplasm of bronchus and lung |
| C34.37 | Malignant neoplasm of bronchus and lung |
| C34.38 | Malignant neoplasm of bronchus and lung |
| C34.39 | Malignant neoplasm of bronchus and lung |
| C34.4 | Malignant neoplasm of bronchus and lung |
| C34.40 | Malignant neoplasm of bronchus and lung |
| C34.41 | Malignant neoplasm of bronchus and lung |
| C34.42 | Malignant neoplasm of bronchus and lung |
| C34.43 | Malignant neoplasm of bronchus and lung |
| C34.44 | Malignant neoplasm of bronchus and lung |
| C34.45 | Malignant neoplasm of bronchus and lung |
| C34.46 | Malignant neoplasm of bronchus and lung |
| C34.47 | Malignant neoplasm of bronchus and lung |
| C34.48 | Malignant neoplasm of bronchus and lung |
| C34.49 | Malignant neoplasm of bronchus and lung |
| C34.5 | Malignant neoplasm of bronchus and lung |
| C34.50 | Malignant neoplasm of bronchus and lung |
| C34.51 | Malignant neoplasm of bronchus and lung |
| C34.52 | Malignant neoplasm of bronchus and lung |
| C34.53 | Malignant neoplasm of bronchus and lung |
| C34.54 | Malignant neoplasm of bronchus and lung |
| C34.55 | Malignant neoplasm of bronchus and lung |
| C34.56 | Malignant neoplasm of bronchus and lung |
| C34.57 | Malignant neoplasm of bronchus and lung |
| C34.58 | Malignant neoplasm of bronchus and lung |
| C34.59 | Malignant neoplasm of bronchus and lung |
| C34.6 | Malignant neoplasm of bronchus and lung |
| C34.60 | Malignant neoplasm of bronchus and lung |
| C34.61 | Malignant neoplasm of bronchus and lung |
| C34.62 | Malignant neoplasm of bronchus and lung |
| C34.63 | Malignant neoplasm of bronchus and lung |
| C34.64 | Malignant neoplasm of bronchus and lung |
| C34.65 | Malignant neoplasm of bronchus and lung |
| C34.66 | Malignant neoplasm of bronchus and lung |
| C34.67 | Malignant neoplasm of bronchus and lung |
| C34.68 | Malignant neoplasm of bronchus and lung |
| C34.69 | Malignant neoplasm of bronchus and lung |
| C34.7 | Malignant neoplasm of bronchus and lung |
| C34.70 | Malignant neoplasm of bronchus and lung |
| C34.71 | Malignant neoplasm of bronchus and lung |
| C34.72 | Malignant neoplasm of bronchus and lung |
| C34.73 | Malignant neoplasm of bronchus and lung |
| C34.74 | Malignant neoplasm of bronchus and lung |
| C34.75 | Malignant neoplasm of bronchus and lung |
| C34.76 | Malignant neoplasm of bronchus and lung |
| C34.77 | Malignant neoplasm of bronchus and lung |
The full ICD-10-CM list includes 295 codes. Pull the complete code set directly from CPB 0825 on the Aetna policy portal before finalizing your charge capture updates.
Get the Full Picture for CPT 94621
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.